Rich Pharmaceuticals contracts oncology clinical study to CMIC ASIA-PACIFIC

Rich Pharmaceuticals Inc. announced this week that CMIC ASIA-PACIFIC PTD. LTD., an Asian contract research organization (CRO), will run the first phase of an upcoming oncology clinical.

Rich Pharmaceuticals emphasizes innovative oncological therapies in its work to develop and commercialize drugs, while CMIC is one of the top CROs for clinical oncology studies in Asia.

The recently announced study will look at the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.

"We are very pleased to have retained the services of a well respected and internationally recognized CRO which specializes in managing clinical studies," Rich Pharmaceuticals CEO Ben Chang said. "After carefully evaluating many competing organizations, we have chosen this CRO based on their extensive experience in managing global clinical trials of medicines."
Want to get notified whenever we write about Rich Pharmaceuticals, Inc. ?
Next time we write about Rich Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Rich Pharmaceuticals, Inc. 9595 Wilshire Blvd Beverly Hills, CA 90212